Key Takeaways
Pfizer Inc.'s fiscal year 2025 (calendar year ended December 31, 2025) was the third year operating after the post-COVID revenue cliff that defined Pfizer's FY2022-FY2023 transition (Comirnaty COVID vaccine revenue declining from approximately $37.8B FY2022 peak to approximately $5-6B in FY2025 as the pandemic transitioned toward endemic surveillance vaccination patterns) and the second full year integrating the Seagen acquisition (the $43B December 2023 transformative deal that added the antibody-drug conjugate franchise — ADCetris, Padcev, Tukysa, Tivdak — to Pfizer's oncology portfolio): revenue of approximately $62-64B (+~5-8% YoY), adjusted operating margin of approximately 30% generating operating income of approximately $19B, and adjusted EPS of approximately $2.85-3.00 on approximately 5.7B diluted shares. The strategic identity that distinguishes Pfizer's contemporary positioning from peer large-cap pharmaceutical companies (Johnson & Johnson covered separately, Merck, Eli Lilly, AbbVie, Bristol-Myers Squibb, Novartis, AstraZeneca) is the deliberate concentration in oncology that resulted from the Seagen acquisition combined with the operational discipline emerging from the multi-year cost reduction program ($4.5B targeted savings by FY2027) that Pfizer announced in late 2023 to address the post-COVID revenue normalization. The investment thesis for Pfizer in FY2026 centers on three structural questions: (1) whether the pre-loss-of-exclusivity (LOE) franchise — Eliquis (oral anticoagulant, jointly developed with Bristol-Myers Squibb, generating approximately $7-8B in Pfizer revenue) faces 2026 generic entry, with Ibrance (CDK4/6 inhibitor for breast cancer, approximately $4B revenue) and Xtandi (prostate cancer, partnered with Astellas, approximately $1.5B Pfizer revenue) facing 2027 patent expirations — can be effectively offset by the post-LOE pipeline launches and Seagen integration synergies; (2) whether the Seagen oncology franchise scales as projected with Padcev (urothelial cancer) and Tukysa (HER2 breast cancer) expanding into new indications; and (3) whether the Albert Bourla cost reduction program delivers the targeted $4.5B savings while preserving R&D pipeline investment that supports the post-LOE growth thesis.
Pfizer Inc. has operated continuously since 1849, when Charles Pfizer and Charles Erhart founded the company in Brooklyn, New York as a fine chemicals manufacturer. The 176-year operational history transformed Pfizer through landmark eras including the antibiotic era of the 1940s-1960s (Pfizer became one of the largest penicillin manufacturers during World War II), the cardiovascular era (Lipitor became the best-selling pharmaceutical in history during the 2000s, generating cumulative revenues exceeding $130B before patent expiration), the oncology era beginning in the 2000s (acquisitions of Pharmacia, Wyeth, Hospira, Medivation, Array BioPharma, Trillium, Arena, Biohaven, Global Blood Therapeutics, and ultimately Seagen progressively built the oncology franchise), and the COVID-19 era that catapulted Pfizer to the largest pharmaceutical company by revenue in FY2021-FY2022 before the rapid normalization. CEO Albert Bourla, who has led Pfizer since January 2019 (succeeding Ian Read), oversaw the COVID-19 vaccine development partnership with BioNTech (the most rapid pharmaceutical product development in history, from initial collaboration announcement in March 2020 to FDA emergency use authorization in December 2020) and the strategic capital deployment that followed: the divestiture of the Consumer Health business through the 2019 joint venture with GlaxoSmithKline (later spun out as Haleon in July 2022, with Pfizer retaining a minority stake), the divestiture of the Upjohn off-patent business through the 2020 combination with Mylan to form Viatris, and the $43B Seagen acquisition that completed in December 2023 to position Pfizer's oncology franchise for the post-LOE growth phase.
Business Structure
Pfizer reorganized its segment reporting structure following the Seagen integration; the contemporary structure organizes around four therapeutic-area-aligned business segments.
Oncology (~$14B revenue, ~22% of total): The strategically most important growth segment post-Seagen acquisition. Major franchises:
- Antibody-Drug Conjugates (ADCs) (Seagen heritage): ADCetris (Hodgkin lymphoma + selected hematology, ~$1B revenue), Padcev (urothelial cancer, ~$2B revenue, FDA approved in combination with Keytruda for first-line metastatic urothelial cancer December 2023), Tukysa (HER2+ breast cancer, ~$700M revenue), Tivdak (cervical cancer, ~$300M revenue).
- Pre-Seagen Pfizer Oncology: Ibrance (CDK4/6 inhibitor for HR+/HER2- breast cancer, ~$4B revenue, facing 2027 patent expiration), Xtandi (androgen receptor inhibitor for prostate cancer, partnered with Astellas, ~$1.5B Pfizer share, facing 2027 LOE), Inlyta (renal cell carcinoma, declining), Bosulif (CML, smaller franchise), Talzenna (BRCA-mutated breast cancer + selected oncology), Adcetris (rebrand pending), Lorbrena (ALK+ NSCLC).
- Newer / Pipeline-Recent Launches: Elrexfio (multiple myeloma bispecific antibody, launched H2 2023), Talvey (multiple myeloma bispecific, partnership with Janssen), selected emerging products.
Internal Medicine (~$14B revenue, ~22% of total): The cardiovascular, diabetes, and selected internal medicine franchises.
- Eliquis (apixaban) (~$7-8B Pfizer revenue): Oral anticoagulant for atrial fibrillation stroke prevention plus venous thromboembolism, joint development with Bristol-Myers Squibb. Eliquis is the largest single Pfizer-branded product by revenue and faces 2026 patent expiration in major markets — the most significant single LOE event in Pfizer's portfolio.
- Vyndaqel/Vyndamax (tafamidis) (~$5-6B revenue): Transthyretin amyloidosis cardiomyopathy treatment, market-leading product in the rare disease subset, growing approximately 10-15% annually as ATTR-CM diagnosis and treatment expands.
- Diabetes/Cardiovascular: Smaller legacy products.
Vaccines (~$8B revenue, ~13% of total): The vaccine franchise post-Comirnaty COVID normalization.
- Prevnar 13/Prevnar 20 (pneumococcal vaccines): ~$5B revenue, the dominant pneumococcal conjugate vaccine globally.
- Comirnaty (COVID vaccine) (~$2B Pfizer revenue at FY2025 normalized rates, declining from peak): Continued surveillance vaccination plus elderly/immunocompromised tier.
- Abrysvo (RSV vaccine, launched Sep 2023): Respiratory syncytial virus vaccine for adults 60+ and pregnant women (maternal immunization for infant protection); ramping from approximately $0.9B FY2024 toward $1-1.5B FY2025.
Specialty Care (~$14B revenue, ~22% of total): Selected smaller franchises including rare disease (Vyjuvek topical gene therapy via Krystal Biotech royalty partnership), neuromuscular, biosimilars portfolio (selected biosimilar products), Sulzer rare disease (Pfizer's selected smaller specialty franchises).
COVID Therapeutics + Vaccines Detail:
- Paxlovid (nirmatrelvir/ritonavir) (~$2-3B FY2025 revenue, declining): Oral COVID-19 antiviral, the dominant outpatient COVID-19 treatment globally.
- Comirnaty COVID vaccine (described in Vaccines segment): ~$2B FY2025 revenue.
Key Core Metrics Performance
Revenue, Margin, and EPS Trajectory (FY2021–FY2025)
| Fiscal Year | Revenue | YoY Growth | Adj. Op. Margin | Adj. EPS |
|---|---|---|---|---|
| FY2021 | ~$81.3B | +95% (Comirnaty + Paxlovid launches) | ~38.5% | ~$4.42 |
| FY2022 | ~$100.3B | +23% (peak COVID revenue) | ~36.5% | ~$6.58 |
| FY2023 | ~$58.5B | -42% (COVID revenue normalization) | ~25.5% | ~$1.84 |
| FY2024 | ~$63.6B | +9% (incl. Seagen partial year + recovery) | ~28.5% | ~$3.11 |
| FY2025 | ~$63B | -1% to +3% (varies on Eliquis LOE timing) | ~30% | ~$2.95 |
The pattern of revenue and margin volatility through the COVID-19 cycle — peak FY2022 revenue $100B at 36.5% operating margin, trough FY2023 revenue $58.5B at 25.5% margin — illustrates the challenge of operating on the post-COVID revenue cliff. The FY2024-FY2025 stabilization at approximately $63B with operating margin recovering toward 30% reflects underlying franchise stability plus Seagen integration economics.
Loss of Exclusivity Cliff Schedule
| Product | Revenue (FY2025) | LOE Date | Estimated Pre-LOE Erosion |
|---|---|---|---|
| Eliquis | ~$7-8B (Pfizer share) | 2026 (US) | ~$3-4B impact through FY2027 |
| Ibrance | ~$4B | 2027 (US) | ~$2-3B impact through FY2028 |
| Xtandi | ~$1.5B | 2027 (US) | ~$0.7-1B impact through FY2028 |
| Inlyta | ~$0.7B | 2025 (US) | ~$0.4-0.5B impact through FY2026 |
| Combined LOE Impact | ~$13-14B | FY2025-FY2028 | ~$6-9B cumulative revenue impact over 3 years |
The aggregate LOE exposure of approximately $13-14B in revenue spread over FY2025-FY2028 represents one of the largest patent cliff exposures among large-cap pharmaceutical companies — the post-LOE pipeline conversion success determines whether Pfizer revenue and EPS growth resume in the FY2026-FY2028 period.
Market Evaluation
Pfizer trades at approximately 8-12x forward adjusted EPS — value-leaning multiples that reflect both the dividend yield (~6-7%) and the LOE cliff overhang. The bull case is Seagen integration + post-LOE pipeline + cost program execution: if Seagen oncology revenue grows from approximately $4B at acquisition close to $7-9B by FY2027 (driven by Padcev expanded indications, Tukysa label growth, plus emerging ADC pipeline), if the pre-LOE pipeline launches (selected oncology + cardiovascular + rare disease assets) collectively replace the LOE revenue at favorable margins, and if the $4.5B cost program delivers as projected, adj. EPS could approach $3.50-4.00 by FY2027 with multiple expansion potential as the LOE cliff narrative resolves. The bear case is LOE cliff exceeding pipeline replacement + competitive intensity: if Eliquis biosimilar entry compresses revenue faster than projected, if Ibrance faces both biosimilar entry and CDK4/6 competitive class compression, or if Seagen pipeline launches encounter regulatory or competitive challenges, EPS could compress toward $2.50-2.80 with limited multiple expansion runway.
The Seagen Integration and Post-LOE Pipeline Conversion Strategy
The strategic argument that frames Pfizer's medium-term thesis rests on the Seagen oncology franchise and the post-loss-of-exclusivity pipeline conversion strategy. Seagen's pre-acquisition revenue was approximately $4B (FY2022), generated primarily by ADCetris (Hodgkin lymphoma franchise launched 2011), Padcev (urothelial cancer launched 2019), Tukysa (HER2+ breast cancer launched 2020), and Tivdak (cervical cancer launched 2021). Seagen's strategic value rested on the antibody-drug conjugate platform — the technology of attaching cytotoxic chemotherapy payloads to monoclonal antibodies for targeted delivery to cancer cells expressing specific surface antigens.
The Seagen integration has progressed approximately on plan through FY2024-FY2025: revenue growth from $4B at acquisition to approximately $5B in FY2025, supported by Padcev's first-line metastatic urothelial cancer label expansion (combined with Keytruda, FDA-approved December 2023, supports significantly broader patient population than prior third-line label), Tukysa's continued growth in HER2+ breast cancer plus the emerging gastric cancer indication, and selected Seagen pipeline asset progression. The FY2026-FY2027 trajectory depends on execution: Padcev's revenue could approach $4-5B by FY2027 if first-line urothelial cancer adoption sustains, Tukysa could approach $1.5-2B with continued indication expansion, and Seagen's pipeline (additional ADC programs in development) could support continued long-term growth.
The post-LOE pipeline conversion challenge is structurally significant: Pfizer faces approximately $6-9B in cumulative revenue erosion over FY2026-FY2028 from Eliquis, Ibrance, and Xtandi LOE events. The company must launch and scale new products at approximately $7-10B in revenue contribution to fully replace the eroding revenue. Pfizer's pipeline includes approximately 100+ programs in clinical development, with key near-term opportunities in oncology (multiple Seagen + heritage Pfizer programs), rare disease (selected programs from Biohaven and Global Blood Therapeutics), and selected internal medicine assets. The execution risk is meaningful — large-cap pharmaceutical companies have historically faced challenges in fully replacing major LOE revenue with new launches at favorable economics, and Pfizer's recent track record of post-LOE revenue replacement (post-Lipitor 2011, post-Celebrex 2014, post-Lyrica 2018) has been mixed.